Here is the main part of the response to the ASX from IIQ.An...

Here is the main part of the response to the ASX from IIQ.

An Abstract accepted by the American Society of Clinical Oncology (ASCO) for a Poster
presentation was published by ASCO online at 5:00 PM (ET) on Thursday, May 22, 2025. See
the Abstract at Appendix 1.
This Abstract contains study results about the performance of the EXO-OC test. The Abstract
details the background, methods, results (including statistics) and conclusions underpinning
the high level results released to the ASX announcement on 3 December 2024 – ‘EXO-OC test
delivers outstanding performance’. Further details on these results were subsequently
referred to in IIQ’s Quarterly Business Update (ASX: 31 January 2025), FY25 Half Year Report
(ASX: 21 February 2025) and recent Investor Presentations (ASX: 19 March 2025) and a 3 April
2025 webinar.
Some shareholders may have missed or misunderstood the significance of our 3 December
2024 ASX release and subsequent related updates noted above and may believe the Abstract
contains new or better information, which is materially price sensitive, that is not the case in
the Company's view.
The new information to be delivered in the Poster presentation at the ASCO Annual Meeting
2025 on 1 June 2025 in Chicago is considered price sensitive. This poster presentation is
currently confidential, tightly held and under embargo by ASCO and due for public release at
7:00 AM (CT) / 8:00 AM (ET) on the day of presentation (Sunday, 1 June 2025) and will be
announced to the ASX before market opens on Monday, 2 June 2025.
Presentation spots at prestigious events such as ASCO’s Annual Meeting are highly sought
after and any early release of the Poster is strictly prohibited under ASCO’s Embargo Policy.
Under ASCO’s Embargo Policy early release results in immediate withdrawal of the Poster
presentation from its allocated spot, risking both reputational and commercial damage with
our collaborators and industry partners, as well as potential adverse consequences regarding
INOVIQ
2 | INOVIQ Limited ASX Release
eligibility or acceptance of future abstracts for oral or poster presentations at future ASCO
events.
Additionally, the University of Queensland is currently drafting an Australian Provisional
Patent Application (APPA) to protect its intellectual property rights covering the exosome
ovarian cancer test. This draft patent application relies on the new data and results contained
in the Poster which have been maintained as a trade secret and remains confidential. The
draft APPA is not sufficiently final and is expected to be completed and lodged with the
Australian Patent Office by 4:00 PM AEST on Friday, 30 May 2025 and relies on the Poster
information remaining confidential until then.
Therefore, IIQ is relying on Listing Rule 3.1A to not announce the Poster presentation early
under Listing Rule 3.1 on the basis that it contains information (data and results) that are the
subject of an APPA that is not sufficiently final, is currently a trade secret,remains confidential
and a reasonable person would not expect the Poster to be released early given the draft
APPA and ASCO’s strict Embargo and the consequences of breaching it as noted above.
IIQ has systems and procedures in place to maintain confidentiality of information to ensure
compliance with listing rules and enable it to rely on Listing Rule 3.1A and acknowledges the
recommendations provided by the Code of Best Practice for Reporting by Life Sciences
Companies in respect of its continuous disclosure obligations.